Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations
Juan Ye, Kun Huang · 2026
Read Emerging strategies in venous thromboembolism: a narrative review of pharmacological innovations by Juan Ye, Kun Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13474715.txt.
Description
Ye and Huang review the next generation of drugs for venous thromboembolism, the vein clots that travel to lungs, with an eye on what current blood thinners leave unsolved. Their 2026 narrative review sorts emerging pharmacology by purpose: preventing clots, treating acute ones, preventing recurrence, and helping the body dissolve clots already formed.
The problem list is quantified. Even on modern direct oral anticoagulants, major bleeding strikes roughly 2 to 4% of patients per year and lesser bleeding 10 to 12%. Meanwhile, 20 to 50% of patients develop post-thrombotic syndrome after a deep vein clot near the hip. Factor XI inhibition is the most mature escape route, with abelacimab, milvexian, and osocimab cutting postoperative clots in orthopedic trials with low bleeding, though treatment-phase proof still trails prophylaxis data.
Catalog record
| CREATOR | Juan Ye, Kun Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |